for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alimera Sciences Inc

ALIM.OQ

Latest Trade

4.45USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.95

 - 

12.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.45
Open
--
Volume
--
3M AVG Volume
1.36
Today's High
--
Today's Low
--
52 Week High
12.21
52 Week Low
3.95
Shares Out (MIL)
6.94
Market Cap (MIL)
31.33
Forward P/E
-9.61
Dividend (Yield %)
--

Next Event

Q4 2021 Alimera Sciences Inc Earnings Release

Latest Developments

More

Alimera Sciences Posts Q3 Loss Per Share Of $0.60

Alimera Sciences Announces Q2 Results

Alimera Sciences And Tanner Pharma Group Initiate Global Named Patient Program For Iluvien

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alimera Sciences Inc

Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

Industry

Biotechnology & Drugs

Contact Info

6120 Windward Pkwy Ste 290

ALPHARETTA, GA

30005-8897

United States

+1.678.9905740

http://www.alimerasciences.com/

Executive Leadership

C. Daniel Myers

Non-Executive Chairman of the Board

Richard S. Eiswirth

President, Chief Executive Officer, Director

J. Phillip Jones

Chief Financial Officer

Philip Ashman

Chief Operating Officer, Senior Vice President - Commercial Operations Europe

David R. Holland

Chief Marketing Officer, Senior Vice President - Corporate Communications and Managed Markets

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

3.750

2019

-2.190

2020

-1.040

2021(E)

-0.470
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.53
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
23.43
Total Debt To Equity (MRQ)
2,871.31
LT Debt To Equity (MRQ)
2,852.06
Return on Investment (TTM)
-2.84
Return on Equity (TTM)
-2.28

Latest News

Latest News

BRIEF-Alimera Sciences Initiates Landmark New Day Clinical Trial To Evaluate Iluvien As Baseline Therapy For Diabetic Macular Edema

* ALIMERA SCIENCES INITIATES LANDMARK NEW DAY CLINICAL TRIAL TO EVALUATE ILUVIEN® AS BASELINE THERAPY FOR DIABETIC MACULAR EDEMA

BRIEF-Alimera Sciences Reports Q1 2020 Financial Results

* ALIMERA SCIENCES ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Alimera Sciences Pre-Announces Expected Top Line Revenue For Q1 2020

* ALIMERA SCIENCES PRE-ANNOUNCES EXPECTED TOP LINE REVENUE FOR Q1 2020 AND PROVIDES COVID-19 BUSINESS UPDATE

BRIEF-Alimera Sciences Says, Has Regained Compliance With NASDAQ Listing Rules - SEC Filing

* ON MARCH 6, RECEIVED LETTER FROM NASDAQ INFORMING THAT CO HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULES - SEC FILING Source text: (bit.ly/3cEClzx) Further company coverage:

BRIEF-Alimera Sciences Reports Fourth Quarter Results

* ALIMERA SCIENCES REPORTS RECORD FOURTH QUARTER AND 2019 RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up